Share on StockTwits

Receptos (NASDAQ:RCPT) CAO David A. Hinkle sold 3,000 shares of Receptos stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $42.69, for a total value of $128,070.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Receptos (NASDAQ:RCPT) traded up 0.74% during mid-day trading on Monday, hitting $47.49. 15,675 shares of the company’s stock traded hands. Receptos has a 52-week low of $15.21 and a 52-week high of $55.00. The stock has a 50-day moving average of $40.6 and a 200-day moving average of $39.28. The company’s market cap is $1.295 billion.

Receptos (NASDAQ:RCPT) last announced its earnings results on Tuesday, August 12th. The company reported ($1.04) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.85) by $0.19. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. On average, analysts predict that Receptos will post $-4.04 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Receptos in a research note on Wednesday, August 13th. They set an “outperform” rating and a $60.00 price target on the stock. Separately, analysts at Nomura initiated coverage on shares of Receptos in a research note on Monday, June 30th. They set a “buy” rating and a $63.00 price target on the stock. Finally, analysts at BMO Capital Markets set a $58.00 price target on shares of Receptos in a research note on Tuesday, June 10th. Three analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $55.00.

Receptos, Inc (NASDAQ:RCPT) is a biopharmaceutical company.

Receive News & Ratings for Receptos Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Receptos Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.